Nobelpharma developed Fostoin in Japan. It will be marketed by Eisai and co-promoted by both companies under a previously concluded marketing agreement.
Fostoin is a water-soluble prodrug of phenytoin injection, a drug that has long been used both in Japan and overseas as a treatment for status epilepticus and other such conditions.
By providing phenytoin as a water-soluble prodrug, the agent will reduce local irritation during intravenous infusion and is expected to enhance tolerability.